

In the Claims:

Please cancel claims 10, 15, 17, 88, 93 and 96 without prejudice.

Please amend claims 1, 13, 87, 89, 90 and 94 as follows:

1. (Currently amended) A composition in dosage form suitable for non-parenteral administration comprising at least one antisense oligonucleotide in an emulsion and ~~at least one penetration enhancer selected from the group consisting of surfactants, fatty acids, a bile salt salts, chelating agents, non-chelating non-surfactant molecules, and combinations thereof,~~ wherein said antisense oligonucleotide modulates expression of a cellular adhesion protein, modulates a rate of cellular proliferation, or has biological activity against eukaryotic pathogens or retroviruses.

2-3. (Cancelled).

4. (Previously presented) The composition of claim 1 wherein said oligonucleotide is a ribozyme or a peptide nucleic acid.

5. (Original) The composition of claim 1 wherein said emulsion is selected from the group consisting of an oil-in-water emulsion, a water-in-oil emulsion, an oil-in-water-in-oil emulsion, and a water-in-oil-in water emulsion.

6. (Original) The composition of claim 1 wherein said emulsion is a microemulsion.

7. (Previously presented) The composition of claim 6 wherein said microemulsion is selected from the group consisting of an oil-in-water microemulsion, a water-in-oil microemulsion, an oil-in-water-in-oil microemulsion, and a water-in-oil-in water microemulsion.

8-11. (Cancelled).

12. (Original) The composition of claim 1 wherein said bile salt is selected from the group consisting of cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, sodium tauro-24,25-dihydrofusidate, sodium glycodihydrofusidate, polyoxyethylene-9-lauryl ether and a pharmaceutically acceptable salt thereof.

13. (Currently amended) The composition of claim 1 wherein said penetration enhancer ~~is a combination of~~ further comprising at least one fatty acid ~~and at least one bile salt~~.

14-18. (Cancelled).

19. (Original) The composition of claim 1 further comprising at least one carrier compound.

20. (Previously presented) The composition of claim 19 wherein said carrier compound is selected from the group consisting of polyinosinic acid, dextran sulfate, polycytidic acid, and 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid.

21-79. (Cancelled).

80. (Previously presented) The composition according to claim 1, wherein said oligonucleotide is SEQ ID NO:1.

81-83. (Cancelled).

84. (previously presented) The composition of claim 1 wherein said emulsion is an oil-in-water-in-oil emulsion or a water-in-oil-in-water emulsion.

85. (previously presented) The composition according to claim 1, wherein said oligonucleotide is selected from the group consisting of SEQ ID NOS: 2, 48, 49, 50, 16, 19, 51, 52, 53, and 54.

86. (Cancelled).

87. (Currently amended) A composition comprising at least one antisense oligonucleotide in an emulsion and ~~at least one penetration enhancer selected from the group consisting of a bile salt salts, chelating agents, non-chelating non-surfactant molecules, and combinations thereof,~~ wherein said antisense oligonucleotide modulates expression of a cellular adhesion protein, modulates a rate of cellular proliferation, or has biological activity against eukaryotic pathogens or retroviruses.

88. (Cancelled).

89. (Currently amended) The composition of claim 87 ~~comprising at least one antisense oligonucleotide in an emulsion~~ further comprising ~~and a mixture of at least one bile salt and~~ at least one fatty acid.

90. (Currently amended) The composition of claim 87, further comprising ~~at least one antisense oligonucleotide in an emulsion and~~ a mixture of fatty acids.

91. (Previously presented) The composition of claim 87 in dosage form suitable for non-parenteral administration.

92. (Previously presented) The composition of claim 87 in oral dosage form.

93. (Cancelled).

94. (Currently amended) The composition of claim 1 further comprising ~~at least one antisense oligonucleotide in an emulsion and~~ a mixture of fatty acids.

95. (Previously presented) The composition of claim 1 in oral dosage form.

96. (Cancelled).